Nyxoah SA — Form 6-K Summary
Business Context and Reporting Period
Nyxoah SA furnished this Form 6-K on May 14, 2024, reporting unaudited first-quarter 2024 financial and operating results. The filing covers the period ended March 31, 2024, although the supplied filing text does not include the underlying results presented in Exhibits 99.1 and 99.2.
Nyxoah is a Belgian foreign private issuer headquartered in Mont-Saint-Guibert, Belgium, and reports annually on Form 20-F.
Financial and Operating Metrics
- Revenue, gross profit, operating loss, net loss, cash flow, margins, cash balance, debt, liquidity, and other financial metrics: the filing text does not provide clear values.
- The filing states that the company announced its first-quarter 2024 results and issued a related first-quarter report, but the detailed figures are contained in the referenced exhibits, which were not included in the supplied text.
Material Changes Versus the Prior Comparable Period
The supplied text does not provide sufficient information to identify changes in revenue, profitability, cash use, liquidity, operating performance, or other metrics versus the first quarter of 2023.
Guidance, Outlook, Risks, and Unusual Items
- No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are described in the supplied Form 6-K text.
- Exhibit 99.1 is a press release dated May 14, 2024, and Exhibit 99.2 is the first-quarter 2024 report.
- Exhibit 99.2 is incorporated by reference into specified Form S-8 and Form F-3 registration statements. Exhibit 99.1 is furnished and generally is not deemed filed under Section 18 of the Exchange Act, subject to the filing’s stated exceptions.
Important Facts for Investors to Verify
- Review Exhibits 99.1 and 99.2 for the actual first-quarter 2024 financial results and operating statistics.
- Verify cash, cash runway, financing activities, debt, and liquidity disclosures.
- Verify revenue growth, gross margin, operating expenses, net loss, and cash-flow trends against the first quarter of 2023.
- Review management’s outlook, clinical and commercial updates, regulatory developments, and any disclosed risks or contingencies.